These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 12128148)
1. In regard to Antonadou et al. Randomized trial investigating the effects of daily amifostine in addition to radiation therapy in 146 patients with advanced lung cancers. Dubray B; Dhermain F Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1395-6; author reply 1396. PubMed ID: 12128148 [No Abstract] [Full Text] [Related]
2. Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation. Arquette M; Wasserman T; Govindan R; Garfield D; Senzer N; Gillenwater H; Socinski M Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):59-61. PubMed ID: 11917286 [TBL] [Abstract][Full Text] [Related]
3. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312 [TBL] [Abstract][Full Text] [Related]
4. A new administration schedule for amifostine as a radioprotector in cancer therapy. Wagner W; Radmard A; Schönekaes KG Anticancer Res; 1999; 19(3B):2281-3. PubMed ID: 10472344 [TBL] [Abstract][Full Text] [Related]
5. What should the optimal timing be for amifostine administration relative to radiation and chemotherapy? Komaki R J Clin Oncol; 2005 Oct; 23(28):7232-3; author reply 7233-5. PubMed ID: 16192612 [No Abstract] [Full Text] [Related]
6. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis. Mell LK; Malik R; Komaki R; Movsas B; Swann RS; Langer C; Antonadou D; Koukourakis M; Mundt AJ Int J Radiat Oncol Biol Phys; 2007 May; 68(1):111-8. PubMed ID: 17289291 [TBL] [Abstract][Full Text] [Related]
7. Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine. Mell LK; Movsas B Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1341-50. PubMed ID: 18798703 [TBL] [Abstract][Full Text] [Related]
8. The potential role of amifostine in the treatment of non small cell lung cancer. Castiglione F; Porcile G; Gridelli C Lung Cancer; 2000 Jul; 29(1):57-66. PubMed ID: 10880848 [TBL] [Abstract][Full Text] [Related]
9. Comment on: 'Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients' Radiother Oncol 70: 261-264, 2004 by Dr Rades et al. Cengiz M; Onal C; Yildiz F; Zorlu AF Radiother Oncol; 2004 Oct; 73(1):109; author reply 109-10. PubMed ID: 15465155 [No Abstract] [Full Text] [Related]
10. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308 [TBL] [Abstract][Full Text] [Related]
11. Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis. Devine A; Marignol L Anticancer Res; 2016 Jan; 36(1):5-12. PubMed ID: 26722022 [TBL] [Abstract][Full Text] [Related]
12. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Antonadou D; Throuvalas N; Petridis A; Bolanos N; Sagriotis A; Synodinou M Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):402-8. PubMed ID: 12957251 [TBL] [Abstract][Full Text] [Related]
13. Amifostine-induced back pain: a case report. Norales G; Maria V; de Guzman A; Leonard R; Aref A Am J Health Syst Pharm; 2006 Feb; 63(4):381-2. PubMed ID: 16452524 [No Abstract] [Full Text] [Related]
14. Use of Amifostine for Cytoprotection during Radiation Therapy: A Review. King M; Joseph S; Albert A; Thomas TV; Nittala MR; Woods WC; Vijayakumar S; Packianathan S Oncology; 2020; 98(2):61-80. PubMed ID: 31846959 [TBL] [Abstract][Full Text] [Related]
18. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC). Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077 [TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01. Werner-Wasik M; Langer C; Movsas B Semin Oncol; 2004 Dec; 31(6 Suppl 18):47-51. PubMed ID: 15726523 [TBL] [Abstract][Full Text] [Related]